Rituximab-responsive nephrotic syndrome due to minimal change disease in systemic lupus erythematosus.
Division of Rheumatology, University of Pennsylvania, Philadelphia, PA 19104, USA. Anupama.Shahane@uphs.upenn.edu
Anupama
A
Shahane
Atul
A
Khasnis
Carmen
C
Gota
D000293:Adolescent; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D004232:Diuretics / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D005665:Furosemide / Q000008:administration & dosage; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D006886:Hydroxychloroquine / Q000008:administration & dosage; D008180:Lupus Erythematosus, Systemic / Q000150:complications*; D009402:Nephrosis, Lipoid / Q000188:drug therapy* / Q000209:etiology; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000209:etiology; D011241:Prednisone / Q000008:administration & dosage; D000069283:Rituximab; D016896:Treatment Outcome
D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D004232:Diuretics; D005938:Glucocorticoids; D000069283:Rituximab; D006886:Hydroxychloroquine; D005665:Furosemide; D011241:Prednisone